Filtered By:
Drug: Avastin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 31 results found since Jan 2013.

Targeting regulation of VEGF by BPTF in non-small cell lung cancer and its potential clinical significance
ConclusionsBPTF positively regulates VEGF expression and its high expression predicts a better efficacy of bevacizumab treatment in NSCLC.
Source: European Journal of Medical Research - December 19, 2022 Category: Research Source Type: research

Combining Bevacizumab with knocked-down β-catenin reduces VEGF-A and Slug mRNA in HepG2 but not in Caco-2 cell lines
CONCLUSION: We conclude that, combining Bevacizumab with knocked down β-catenin reduce the expression of VEGF-A and Slug in HepG2 but not in Caco-2 cells.PMID:34429048 | DOI:10.2174/1573405617666210824120618
Source: Molecular Medicine - August 25, 2021 Category: Molecular Biology Authors: Reem Mebed Yasser Bm Ali Nahla Shehata Nadia El-Guendy Nahla Gamal Abdel-Rahman Zekri Salwa Sabet Source Type: research

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
In this research, we analyze a relationship between CD44 expression and responsiveness to Bev and elucidate the role of CD44 in anti ‐VEGF therapy. These results indicate CD44 will be a useful biomarker for predicting responsiveness to bevacizumab and may serve as a therapeutic target in both primary and recurrent GBMs. AbstractAntiangiogenic therapy with bevacizumab (Bev), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a common treatment for recurrent glioblastoma (GBM), but its survival benefit is limited. Resistance to Bev is thought to be a major cause of ineffectiveness on Bev therapy....
Source: Cancer Medicine - February 5, 2021 Category: Cancer & Oncology Authors: Masahiro Nishikawa, Akihiro Inoue, Takanori Ohnishi, Hajime Yano, Yonehiro Kanemura, Shohei Kohno, Shiro Ohue, Saya Ozaki, Shirabe Matsumoto, Satoshi Suehiro, Yawara Nakamura, Seiji Shigekawa, Hideaki Watanabe, Riko Kitazawa, Junya Tanaka, Tags: ORIGINAL RESEARCH Source Type: research

Cancers, Vol. 12, Pages 3531: Targeting the RhoGEF βPIX/COOL-1 in Glioblastoma: Proof of Concept Studies
elers Marc Symons Annette T. Byrne Glioblastoma (GBM), a highly invasive and vascular malignancy is shown to rapidly develop resistance and evolve to a more invasive phenotype following bevacizumab (Bev) therapy. Rho Guanine Nucleotide Exchange Factor proteins (RhoGEFs) are mediators of key components in Bev resistance pathways, GBM and Bev-induced invasion. To identify GEFs with enhanced mRNA expression in the leading edge of GBM tumours, a cohort of GEFs was assessed using a clinical dataset. The GEF βPix/COOL-1 was identified, and the functional effect of gene depletion assessed using 3D-boyden cham...
Source: Cancers - November 26, 2020 Category: Cancer & Oncology Authors: Kate Connor David W. Murray Monika A. Jarzabek Nhan L. Tran Kieron White Patrick Dicker Kieron J. Sweeney Philip J. O ’Halloran Brian MacCarthy Liam P. Shiels Francesca Lodi Diether Lambrechts Jann N. Sarkaria Raymond M. Schiffelers Marc Symons Annette Tags: Article Source Type: research

Systemic Delivery of NAC-1 siRNA by Neuropilin-Targeted Polymersomes Sensitizes Antiangiogenic Therapy of Metastatic Triple-Negative Breast Cancer.
Abstract Antiangiogenic therapy with bevacizumab while being interesting for metastatic triple-negative breast cancer (mTNBC) is restrained by tumor hypoxia elevation and cancer stem cell enrichment. Here, we find that neuropilin-1 (NRP-1)-targeted delivery of nucleus accumbens-associated protein-1 (NAC-1) siRNA mediated by tLyP-1 peptide-functionalized chimaeric polymersomes (tLyP-1-Ps) effectively sensitizes antiangiogenic therapy of mTNBC in vivo. tLyP-1-Ps showed good encapsulation (up to 14.4 wt. %) of siNAC-1, giving robust tLyP-1-Ps-siNAC-1 nanoformulation with a defined size of 48.5 nm (PDI = 0.13) and a s...
Source: Biomacromolecules - November 11, 2020 Category: Biochemistry Authors: Wang H, Wang X, Zhang Y, Cheng R, Yuan J, Zhong Z Tags: Biomacromolecules Source Type: research

VEGF Production Is Regulated by the AKT/ERK1/2 Signaling Pathway and Controls the Proliferation of Toxoplasma gondii in ARPE-19 Cells
The retina is the primary site of Toxoplasma gondii infection in the eye, and choroidal neovascularization in ocular toxoplasmosis is one of the most important causes of visual impairment. Vascular endothelial growth factor (VEGF) is one of the key regulators of blood vessel development, however, little is known about the mechanisms of T. gondii-induced VEGF production in ocular toxoplasmosis. Here, we investigate the effect of T. gondii on VEGF production regulation in human retinal pigment epithelium ARPE-19 cells and attempted to unveil the underlying mechanism of this event by focusing on the interaction between parasi...
Source: Frontiers in cellular and infection microbiology - April 27, 2020 Category: Microbiology Source Type: research

Effect of bevacizumab on the tight junction proteins of vascular endothelial cells.
This study aimed to investigate how bevacizumab, a vascular endothelial growth factor A (VEGFA) neutralizing antibody applied in clinic, affects the tight junction protein CLDN5 and subsequently influences tumor cell invasion and potential metastasis. Western-blot, quantitative real-time polymerase chain reaction (q-PCR), immunofluorescence and immunohistochemistry revealed that low-dose bevacizumab up-regulated CLDN5, whereas high-dose bevacizumab down-regulated CLDN5. Cell migration, invasion and permeation assay demonstrated that high-dose bevacizumab enhanced the migration, invasion and permeation abilities of human um...
Source: American Journal of Translational Research - October 23, 2019 Category: Research Tags: Am J Transl Res Source Type: research

Gene Therapy Leaves a Vicious Cycle
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - April 23, 2019 Category: Cancer & Oncology Source Type: research